From Patents to Public Health: The GLP-1 Journey

In this insightful episode, host Lucy Chard is joined by Aurelio Arias from IQVIA to explore the transformative role of GLP-1 therapies in clinical obesity treatment and the technological advancements driving their success. Aurelio delves into how these medications are revolutionising care, offering hope to millions worldwide. A key focus is the upcoming patent expiry of semaglutide in 2026, which could significantly impact affordability and global access, sparking discussions on equitable distribution.

Episode metadata supplied by the publisher feed · Published Oct 20, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

From Patents to Public Health: The GLP-1 Journey

0:00 34:31

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of CPHI Podcast Series?

This episode is 34 minutes long.

When was this CPHI Podcast Series episode published?

This episode was published on October 20, 2025.

Can I download this CPHI Podcast Series episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!